Antiviral treatments
The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
1. A method for treating an influenza viral infection in a human comprising administering in multiple intravenous administrations for up to 20 days, the multiple intravenous administrations providing an effective anti-viral amount of up to 1,000 mg of a compound of formula I or formula Ia:
or a pharmaceutically acceptable salt thereof, to the human, wherein the influenza viral infection is a type A, type B, H3N2, H1N1, H5N1, avian, or seasonal influenza viral infection.
2. The method of claim 1 , wherein the compound of formula I is a compound of formula Ia:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 500 mg.
4. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 400 mg.
5. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 300 mg.
6. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 200 mg.
7. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 150 mg.
8. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 75 mg.
9. The method of claim 1 , wherein the effective anti-viral amount is 600 mg.
10. The method of claim 1 , wherein the effective anti-viral amount is about 300 mg.
11. The method of claim 1 , wherein the influenza viral infection is the type A influenza viral infection.
12. The method of claim 1 , wherein the influenza viral infection is the type B influenza viral infection.
13. The method of claim 1 , wherein the influenza viral infection is the seasonal influenza viral infection.
14. The method of claim 1 , further comprising orally administering a neuraminidase inhibitor to the human.
15. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is oseltamivir carboxylate.
16. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof.
17. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, IIa, IIIa, or IVa:
or a pharmaceutically acceptable salt thereof.
18. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia,
or a pharmaceutically acceptable salt thereof.
19. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 20 days.
20. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 10 days.
21. The method of claim 14 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 5 days.
22. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 8000 mg.
23. The method of claim 1 , wherein the effective anti-viral amount is less than or equal to 8000 mg.